VANCOUVER, BRITISH COLUMBIA--(Marketwire - Nov. 20, 2012) - Sirona Biochem Corp. (TSX VENTURE:SBM)(PINKSHEETS:SRBCF)(FRANKFURT:ZSB), an award-winning biotech company, is pleased to announce its subsidiary company, TFChem, is the recipient of the 2012 INPI Regional Trophy for Innovation. INPI is the National Institute of Industrial Property (Institut National de la Propriété Industrielle), a French organization supporting patent applications.
"France is home to some of the world's most innovative science and we are so honoured to have received this prestigious award. This trophy is a recognition of the strength of our patent strategy," said Dr. Géraldine Deliencourt-Godefroy.
"Congratulations to Géraldine and the TFChem team for winning the INPI Trophy," said Neil Belenkie, Chief Executive Officer at Sirona Biochem. "The scientific advances in carbohydrate chemistry made by Géraldine and the TFChem chemistry team exemplify dedication, entrepreneurship and innovation. This honour is well-deserved," he added.
Since 1991, the INPI has annually awarded regional and national trophies to acknowledge innovation in France. Small and medium-sized enterprises (SMEs) and Research Units are measured for their intellectual property strength and strategies, competitive advantage, growth potential, partnerships and application of technology. Each year INPI awards three companies and one research units per region.
View the video of TFChem (in French).
Read about this year's INPI Winners (in French).
TFChem, a subsidiary of Sirona Biochem Corp., is a drug-discovery company which uses fluorine atom properties to develop new glycomimetic compounds. TFChem is a leader in the area of fluorinated glycosides and their application in developing new, more potent and safer pharmaceutical and cosmetic agents. For more information visit www.tfchemistry.com.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes therapeutics, cancer vaccine antigens, skin depigmenting and anti-aging agents for cosmetic use, and biological ingredients. The company utilizes a proprietary chemistry technique to improve pharmaceutical properties of carbohydrate-based molecules. For more information visit www.sironabiochem.com.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.